| 1. |
強甜甜, 高自清. 糖尿病性黃斑水腫的治療進展[J]. 齊齊哈爾醫學院學報, 2022, 43(22): 2162-2166. DOI: 10.3969/j.issn.1002-1256.2022.22.015.Qiang TT, Gao ZQ. Progress in the treatment of diabetic macular edema[J]. Journal of Qiqihar Medical University, 2022, 43(22): 2162-2166. DOI: 10.3969/j.issn.1002-1256.2022.22.015.
|
| 2. |
Nakao S, Kusuhara S, Murakami T. Anti-VEGF therapy for the long-term management of diabetic macular edema: a treat-to-target strategy based on macular morphology[J]. Graefe's Arch Clin Exp Ophthalmol, 2024, 262(12): 3749-3759. DOI: 10.1007/s00417-024-06558-y.
|
| 3. |
龔軼, 邵彥, 李筱榮. 抗血管內皮生長因子藥物治療糖尿病黃斑水腫臨床試驗的研究與進展[J]. 中華眼底病雜志, 2022, 38(1): 66-71. DOI: 10.3760/cma.j.cn511434-20210524-00268.Gong Y, Shao Y, Li XR. Research and progress in clinical trials of anti-vascular endothelial growth factor drugs in the treatment of diabetic macular edema[J]. Chin J Ocul Fundus Dis, 2022, 38(1): 66-71. DOI: 10.3760/cma.j.cn511434-20210524-00268.
|
| 4. |
Taniguchi H, Yoshida I, Sakamoto M, et al. Epiretinal membrane appearance or progression after intravitreal injection in age-related macular degeneration[J/OL]. BMC Ophthalmol, 2021, 21(1): 190[2021-04-28]. https://pubmed.ncbi.nlm.nih.gov/33906612/. DOI: 10.1186/s12886-021-01944-0.
|
| 5. |
Altintas AGK, Ilhan C. Effects of the epiretinal membrane on the outcomes of intravitreal dexamethasone implantation for macular edema secondary to branch retinal vein occlusion[J]. Arq Bras Oftalmol, 2023, 86(1): 13-19. DOI: 10.5935/0004-2749.20230011.
|
| 6. |
顏萌, 王文營, 鄭召霞, 等. 糖尿病黃斑水腫患者抗VEGF治療的長期療效觀察及其與視網膜前膜的關系[J]. 臨床醫學進展, 2022, 12(3): 1646-1653. DOI: 10.12677/acm.2022.123237.Yan M, Wang WY, Zheng ZX, et al. The long-term efficacy of anti-vascular endothelial growth factor therapy in diabetic macular edema patients and relationship of epiretinal membrane[J]. Adv Clin Med, 2022, 12(3): 1646-1653. DOI: 10.12677/acm.2022.123237.
|
| 7. |
Vujosevic S, Toma C, Villani E, et al. Diabetic macular edema with neuroretinal detachment: OCT and OCT-angiography biomarkers of treatment response to anti-VEGF and steroids[J]. Acta Diabetol, 2020, 57(3): 287-296. DOI: 10.1007/s00592-019-01424-4.
|
| 8. |
Wilkinson CP, Ferris FL 3rd, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales[J]. Ophthalmology, 2003, 110(9): 1677-1682. DOI: 10.1016/S0161-6420(03)00475-5.
|
| 9. |
Frank RN, Amin RH, Eliott D, et al. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes[J]. Am J Ophthalmol, 1996, 122(3): 393-403. DOI: 10.1016/s0002-9394(14)72066-5.
|
| 10. |
Nam DH, Oh J, Roh JH, et al. Different expression of vascular endothelial growth factor and pigment epithelium-derived factor between diabetic and non-diabetic epiretinal membranes[J]. Ophthalmologica, 2009, 223(3): 188-191. DOI: 10.1159/000198686.
|
| 11. |
Chang CK, Cheng CK, Peng CH. The incidence and risk factors for the development of vitreomacular interface abnormality in diabetic macular edema treated with intravitreal injection of anti-VEGF[J]. Eye (Lond), 2017, 31(5): 762-770. DOI: 10.1038/eye.2016.317.
|
| 12. |
Moradian S, Ahmadieh H, Malihi M, et al. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy[J]. Graefe's Arch Clin Exp Ophthalmol, 2008, 246(12): 1699-1705. DOI: 10.1007/s00417-008-0914-4.
|
| 13. |
Honda S, Hirabayashi H, Tsukahara Y, et al. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity[J]. Graefe's Arch Clin Exp Ophthalmol, 2008, 246(7): 1061-1063. DOI: 10.1007/s00417-008-0786-7.
|
| 14. |
Sreenivas Bk A, Simakurthy S, Shanmugam PM, et al. Commonalities between fibrotic and inflammatory mechanisms in proliferative vitreoretinopathy and proliferative diabetic retinopathy[J/OL]. Exp Eye Res, 2025, 258: 110482[2025-06-09]. https://pubmed.ncbi.nlm.nih.gov/40499707/. DOI: 10.1016/j.exer.2025.110482.
|
| 15. |
Kang YK, Park HS, Park DH, et al. Incidence and treatment outcomes of secondary epiretinal membrane following intravitreal injection for diabetic macular edema[J/OL]. Sci Rep, 2020, 10(1): 528[2020-01-17]. https://pubmed.ncbi.nlm.nih.gov/31953511/. DOI: 10.1038/s41598-020-57509-6.
|
| 16. |
Kakihara S, AbdelSalam M, Zhuang K, et al. Epiretinal membrane is associated with diabetic retinopathy severity and cumulative anti-VEGF injections[J/OL]. Ophthalmol Sci, 2025, 5(3): 100733[2025-02-07]. https://pubmed.ncbi.nlm.nih.gov/40161463/. DOI: 10.1016/j.xops.2025.100733.
|
| 17. |
Zhang J, Zhang J, Zhang C, et al. Diabetic macular edema: current understanding, molecular mechanisms and therapeutic implications[J/OL]. Cells, 2022, 11(21): 3362[2022-10-25]. https://pubmed.ncbi.nlm.nih.gov/36359761/. DOI: 10.3390/cells11213362.
|
| 18. |
夏沁韻, 陳震, 邢怡橋. 玻璃體黃斑界面異常的糖尿病黃斑水腫研究新進展[J]. 武漢大學學報(醫學版), 2020, 41(5): 853-856. DOI: 10.14188/j.1671-8852.2019.0049.Xia QY, Chen Z, Xing YQ. Research progress of diabetic macular edema with vitreomacular interface abnormality[J]. Medical Journal of Wuhan University, 2020, 41(5): 853-856. DOI: 10.14188/j.1671-8852.2019.0049.
|
| 19. |
Arthi M, Sindal MD, Rashmita R. Hyperreflective foci as biomarkers for inflammation in diabetic macular edema: retrospective analysis of treatment na?ve eyes from south India[J]. Indian J Ophthalmol, 2021, 69(5): 1197-1202. DOI: 10.4103/ijo.IJO_2627_20.
|
| 20. |
張娟娟, 霍昭. 影像生物標志物在糖尿病黃斑水腫中的研究進展[J]. 臨床醫學進展, 2023, 13(3): 4538-4544. DOI: 10.12677/ACM.2023.133651.Zhang JJ, Huo Z. Research progress of imaging biomarkers in diabetic macular edema[J]. Adv Clin Med, 2023, 13(3): 4538-4544. DOI: 10.12677/ACM.2023.133651.
|